Patent · US Active

Liquid oral formulations for sildenafil

US11337979B2 · kind B2 · utility

3Cited by
0References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 16, 2021
Grant dateMay 24, 2022
Priority date
Expiry dateAug 16, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K47/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.